The global gene editing market is expected to reach the market value of around US$ 9.2 Bn by 2026, growing at a CAGR of 15.3% over the forecast period 2019 to 2026.
Gene editing is a type of genetic engineering in which DNA is inserted, deleted, replaced, or modified within a cell. An enzyme is used to cuts the DNA at a specific sequence, and then ‘edit’ is made to the sequence. Gene editing technology can be used for various applications such as to treat diseases, for research, and in agriculture field to increase crop yield by modifying genetic structure. Various techniques used for gene editing. CRISPR-Cas9 is the most commonly used, economical, and efficient system used for genome editing. Some of the other major techniques used for gene editing are zinc-finger nucleases (ZFNs) and TALENs (Transcription activator-like effector nucleases).
Technological advancement in the biotechnological field is anticipated to propel the market during the forecast period. Advancements in gene editing technology help to develop efficient techniques to treat genetic diseases as compared to conventional therapies. For instance, recently developed CRISPR-Cas9 systems are being used extensively as it is more accurate, efficient than the existing methods, and economical.
An increase in demand for synthetic genes in the North America and Asia Pacific regions and growing funding for genetic research in developed as well as developing countries will boost the gene editing market in the coming years. Genetic research involves the study of genes at the molecular level. The data obtained during research can be useful in the process of gene editing that proves beneficial for the growth of the industry. However, stringent government regulations may limit industry growth in the forecast years to some extent.
Based on technology, the market has been segmented into Clustered regularly interspaced short palindromic repeats (CRISPR), Transcription activator-like effect or nuclease (TALEN), Zinc Finger Nuclease (ZFN), and other technologies. CRISPR accounted for the largest share of the market due to a wide range of advantages such as availability of tailor-made option specific to the patient’s mutations for the disease like cystic fibrosis, government initiatives for the development of drug, devices, and vaccines, and investment by market players. For instance, in October 2017, Thermo Fisher Scientific and Synthego collaborated to manufacture and distribute synthetic guide RNA products for CRISPR genome engineering. Furthermore, CRISPR is easy to use, works with high throughput, and affordable technology.
Based on the application, the global gene editing market is divided into cell line editing, animal genome editing, plant genome editing, and others. In 2018, the animal genetic engineering segment accounted for the largest share of the market. Extensive use of gene-editing technology for altering the animal genome sequence to obtain maximum output from domestic animals is a key factor for the dominance of the segment.
Based on the end-users, the market has been segmented into pharmaceutical &biotechnology companies, academics and government research institutes, and Clinical Research Organizations (CRO). Pharma and biotech companies dominated the market in 2018 and are expected to maintain their dominance during the forecast period. The increasing number of rare diseases and patients and growing investment by pharma and biotech companies to develop new drugs against these rare diseases are the key driving factors of the segment.
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa are the major regions. Currently, North America holds the largest share of the global gene editing market and is anticipated to maintain its position during the forecast period. This can be attributed to the local presence of major market players, early adoption of the latest technology of gene editing, and higher awareness about benefits associated with gene editing. Furthermore, high government funding and investments by market players for research and development activities on genetic modification further boost the market. The Asia Pacific is expected to grow at a steady rate due to the slow adoption of technology and an unorganized regulatory environment across and within countries. However, government funding, an increasing number of laboratories, and investment by market players are expected to propel the market growth. China dominates the market due to high penetration and more research. Patent applications from China for CRISPR have climbed rapidly in the last few years, and hence the country dominates in the industrial and agricultural fields.
The market research study on “Gene Editing Market – Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 – 2026”, offers a detailed insight on the global gene editing market entailing insights on its different market segments. Market dynamics with drivers, restraints, and opportunities with their impact are provided in the report. The report provides insights into the global gene editing market, its technology, application, end-user, and major geographic regions. The report covers basic development policies and layouts of technology development processes. Secondly, the report covers global gene editing market size and segment markets by technology, application, end-user, and geography along with the information on companies operating in the market. The gene editing market analysis is provided for major regional markets including North America, Europe, Asia Pacific, Latin America and Middle East and Africa. For each region, the market sizes for different segments have been covered under the scope of the report.
Key players operating in the gene editing market are Addgene, Allele Biotech, Bio-Rad, Caribou Biosciences, Inc., CRISPR Therapeutics, Dharmacon Inc., GE Healthcare, GeneCopoeia, Inc., GenScript Corporation, Horizon Discovery Group plc, Integrated DNA Technologies, OriGene Technologies, Merck Millipore Limited, Precision Biosciences, Sangamo Biosciences, Inc., Takara Bio, Agilent Technologies, Inc., and Thermo Fisher Scientific. Mergers, acquisitions, and partnerships are the key strategies being adopted by the market players since the last few years.
Market By Technology
Middle East & Africa
Gene editing is a type of genetic engineering in which DNA is inserted, deleted, replaced, or modified within a cell.
Gene editing is used to treat diseases, for research, and in agriculture field to increase crop yield by modifying genetic structure.
Technological advancement in the biotechnological field is anticipated to propel the market during the forecast period.
According to Acumen Research and Consulting, The gene editing market is expected to reach the market value of around US$ 9.2 Bn by 2026.
The gene editing market is expected to grow at a CAGR of around 15.3% during the forecast period 2019 to 2026.
North America holds the largest share of the global gene editing market.
Addgene, Allele Biotech, Bio-Rad, Caribou Biosciences, Inc., CRISPR Therapeutics, Dharmacon Inc., GE Healthcare, and GeneCopoeia, Inc. are the top players of gene editing market.